59 results about "Tocotrienol" patented technology

The invention discloses a high-yield delta-tocotrienol genetically engineered bacterium and application thereof, and belongs to the technical field of gene recombination. The invention discloses a genetically engineered bacterium for high yield of delta-tocotrienols, which is characterized in that yarrowia lipolytica ATCC MYA-2613 is used as an original strain, and a ku70 gene is knocked out; the gene is used for expressing and coding 4-hydroxyphenylpyruvate dioxygenase, the gene is used for coding uromelanic acid phytate transferase and the gene is used for coding tocopherol cyclase; intensifying a shikimic acid pathway; a mevalonic acid pathway is strengthened; an isopentenol path is introduced; carrying out protein fusion on the HPD and the HPT; truncating a signal peptide of a gene encoding a tocopherol cyclase and back-filling a leucine defect. The genetically engineered bacterium constructed by the invention has industrial stability, can be amplified by more than 10 times in a 2L fermentation tank level compared with a shake flask level, can produce 616.45 mg / L of delta-tocotrienol after being cultured for 240 hours, and has industrial application prospects.

The invention relates to application of a vitamin E compound in preparation of a MACIR protein targeting agent. The vitamin E compound comprises any one or a combination of at least two of tocopherol, tocopherol derivatives, tocotrienol or tocotrienol derivatives. The invention creatively discovers the interaction between tocopherol, tocopherol derivatives, tocotrienol or tocotrienol derivatives and MACIR protein, and proves the strong binding capacity of tocopherol or derivatives thereof and MACIR protein through experiments. The tocopherol, the tocopherol derivative, the tocotrienol or the tocotrienol derivative can be used for regulating the function of MACIR protein associated immune cells so as to influence the expression of inflammatory factors, play an important role in inflammation and anaphylaxis, and also can be used for improving skin injury repair.

The present invention relates to a process for obtaining minor components from vegetable oils, and wherein the vegetable oil includes palm oil, palm olein, palm mid-fraction or mixtures thereof and wherein the minor components of interest are squalene, tocopherols, and optionally tocotrienols. The process is comprising, a fractionation in short path evaporator followed by a further fractionation in short path evaporator. The feed stream may be a condensate stream from a deodorization step.

The present disclosure relates to the use of tocotrienols in pharmaceutical, veterinary and cosmetic applications, namely, by stabilizing tocotrienols without interfering with their function in the skin, particularly in cosmetic formulations. In particular, the disclosure relates to the modification of tocotrienols with nicotinic acid, stabilizing the molecules and their penetration in human skin. The subject compounds and compositions are useful in the medical, veterinary and cosmetic industries, namely, for the prevention, therapy and treatment of skin diseases, skin disorders, or as a therapy or treatment for acne, seborrheic dermatitis, or as anti-aging agents.

The invention relates to application of gamma-tocotrienol in treating cardiac fibrosis, in particular to cardiac fibrosis caused by aortic stenosis and / or myocardial ischemia reperfusion. The administration of the gamma-tocotrienol can significantly relieve cardiac inflammation caused by aortic stenosis and / or myocardial ischemia reperfusion, and effectively inhibit cardiac fibrosis.

The present invention relates to a process for the preparation of vitamin E derivatives, in particular a process for the synthesis of delta-tocotrienols of formula (I). # imgabs0 #

The application relates to the field of cosmetics, and relates to an anti-aging cosmetic, grape pomace oil and a preparation method thereof. The anti-aging cosmetic comprises grape pomace oil; characteristic components of the grape pomace oil include oleanolic acid, alpha-guaiacwoodene, beta-tocotrienol, beta-sitosterol, campesterol, soybean sapogenol E, ganoderic acid F, ganoderol I and D-erythro-dihydrosphingosine; the total phenol content of the grape pomace oil is greater than or equal to 1 mg / g, the total sterol content of the grape pomace oil is greater than or equal to 26 mg / g, and the total flavonoid content of the grape pomace oil is greater than or equal to 1 mg / g; the grape pomace oil is extracted from grape pomace; the grape pomace is mainly composed of grape skin, grape stem and grape seed. The compounds have excellent antioxidant properties and can improve the anti-aging effect of the anti-aging cosmetic. The compounds are helpful for protecting the skin from oxidative damage and play a positive role in cosmetics. The grape pomace oil maximally retains active components of all parts of the grape pomace.

The present invention relates to the formation of a compound of formula (I) by a ring closure reaction of a compound of formula (II) in the presence of a catalytic amount of base. It has been found that this reaction is very efficient, for example providing an efficient route to the synthesis of 3,4-dehydro-α-tocotrienol, α-tocotrienol and α-tocopherol, respectively.

The present invention relates to pharmaceutical compositions formulated for transmucosal delivery and in particular sublingual delivery, which pharmaceutical compositions include at least one tocotrienol or its derivatives, together with one or more pharmaceutically acceptable excipients. The present invention further relates to the use of said compositions for treating or preventing post-exercise muscle soreness, delayed muscle soreness, myocardial fibrosis, hypertension, inflammation, stroke, cancer, high cholesterol and / or triglycerides, alopecia, hypertrophy, conditions caused by radiation exposure, stabilizing and / or controlling blood sugar levels, and improving exercise endurance and performance.

The invention relates to the field of bioengineering and chemical synthesis, in particular to a geranyl geraniol synthetase mutant and application thereof, the amino acid sequence of geranyl geraniol synthetase is selected from any one of the following (a) or (b): (a) an amino acid sequence obtained by substitution, deletion or addition of at least one amino acid to a sequence as shown in SEQ ID No: 1 and derivation; (b) an amino acid sequence having at least 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with (a). The invention provides a brand new method for efficiently producing alpha-tocotrienol by constructing a geranyl geraniol synthesis route in saccharomyces cerevisiae to obtain a genetic engineering strain and then chemically synthesizing alpha-tocotrienol by using geranyl geraniol from a biological source as a raw material.

The present invention provides a liquid enzyme preparation of an enzyme having excellent activity stability. Stability of enzymatic activity is improved by accommodating a liquid enzyme preparation that includes an enzyme into a container the internal space of which has been replaced by an inert gas, or by adding, to a liquid enzyme preparation containing a protein deamidase, an additive selected from the group consisting of sugar alcohols, glycerin, ethanol, sulfites, lecithins, citrates, polyphosphates, tartrates, phytic acid, metaphosphoric acid, sodium chloride, tocotrienols, methionine, pectins, beet pigment, capsicum pigment, rosemary extract, tocopherols, tea extract, and butylated hydroxyanisole.

The invention provides a tocotrienol ether derivative as shown in a formula I, and an isomer, a prodrug, a pharmaceutically acceptable salt, a hydrate or a solvent compound of the tocotrienol ether derivative, r is selected from hydrogen, a substituted or unsubstituted alkyl group with 1 to 10 carbon atoms, a substituted or unsubstituted alkenyl group with 2 to 10 carbon atoms, a substituted or unsubstituted alkynyl group with 2 to 10 carbon atoms, a substituted or unsubstituted aryl group with 6 to 20 carbon atoms, or a substituted or unsubstituted heteroaryl group with 5 to 12 members, a substituted or unsubstituted cycloalkyl group with 3 to 8 carbon atoms or a heterocycloalkyl group with 3 to 8 carbon atoms. The derivative has a better effect on the whole, and is expected to actually become a potential and lasting radiation protective agent aiming at H-ARS.

This invention relates to the field of nanomedicine formulation technology, and discloses a ROS-responsive astaxanthin nanoparticle, its preparation method, and its application. The preparation method includes: catalyzing the transketalization reaction of 3-mercaptopropionic acid with 2,2-dimethoxypropane using an alcohol-water tolerant Lewis acid catalyst (preferably scandium trifluoromethanesulfonate) to prepare a thioketal monomer containing dual-terminated carboxyl groups; coupling the thioketal monomer with stearyl alcohol and methoxy polyethylene glycol using a stepwise sequential coupling strategy to construct an amphiphilic polymer with thioketal bonds as ROS-responsive connecting units; co-dissolving the polymer, astaxanthin, and tocotrienols in tetrahydrofuran, and preparing the nanoparticles using a multi-inlet micro-collision flow nanoprecipitation process. The resulting nanoparticles have a particle size of 100 nm to 200 nm, an astaxanthin encapsulation rate of 90% to 99%, and achieve targeted release in response to reactive oxygen species in the pathological microenvironment. Astaxanthin and tocotrienols synergistically exert antioxidant effects.

The present invention provides a pharmaceutical composition containing a benzodiazepine drug. [Solution] A drug solution for intranasal administration is provided, comprising: (a) a benzodiazepine drug; (b) one or more natural or synthetic tocopherols or tocotrienols, or any combination thereof, in an amount of about 30% to about 95% (w / w); (c) one or more alcohols or glycols, or any combination thereof, in an amount of about 10% to about 70% (w / w); and (d) an alkyl glycoside.

This disclosure relates to an embodiment of the use of tocotrienols in pharmaceutical, veterinary, or cosmetic applications, particularly in cosmetic formulations, whereby stabilizing tocotrienols does not impair their function in the skin. Specifically, this disclosure relates to the modification, molecular stabilization, and penetration properties of tocotrienols in human skin using nicotinic acid. The compounds and compositions of this subject matter are useful in the medical, veterinary, or cosmetic industries as a preventative, therapeutic, or treatment of dermatological diseases or skin disorders, as a treatment or treatment of acne or seborrheic dermatitis, or as anti-aging agents.

The disclosure provides compositions and methods for promoting hair growth and reducing hair loss using bioactive extracts of curcumin, Withania somnifera, and saw palmetto. Tocotrienols, tocopherols, piperine extract, low molecular weight collagen, and hyaluronic acid are optionally included in the compositions and methods

Disclosed are compositions comprising delta-tocotrienol and methods for using the same in the prevention of cancer progression. The methods comprise of reducing, inhibiting, decreasing, and / or preventing the progression of a neoplasm to a cancer (including, but not limited to lung cancer, ovarian cancer, breast cancer, rectal cancer, pancreatic, colon cancer, or intraductal papillary mucinous neoplasm (IPMN) to pancreatic ductal adenocarcinoma) in a subject comprising administering to a subject a therapeutically effective amount of a composition comprising delta-tocotrienol (d-T3).

Nutritionally enhanced nutraceutical Hydrophilic and Lipophilic Rice Bran Fractions from rice bran are provided, as well as a method of using the same to reduce Insulin Resistance in animals, especially humans with pre-diabetes and Type 2 diabetes or others with symptoms of Metabolic Syndrome. Provided in various example embodiments are mixtures of elevated levels of nutraceutical compounds, including but not limited to gamma-oryzanol, inositol, ferulic acid, tocotrienols and phytosterols and pharmaceutical and nutritional compositions thereof. Steps are provided including evaluating insulin resistance parameters, initiating therapy including providing therapeutic amounts of Hydrophilic and Lipophilic Rice Bran Fractions from rice bran to treat pre-diabetes and Type 2 diabetes or others with symptoms of Metabolic Syndrome, managing compliance with the therapy, and monitoring and reevaluating the therapy.

The application relates to an application of a geranylgeranyl pyrophosphate reductase in preparation of tocopherol, wherein a nucleotide sequence coding the geranylgeranyl pyrophosphate reductase is shown as SEQ ID No. 11, and the application comprises the following steps: under the assistance of coenzyme iron-oxidation-reduction protein and iron-oxygen-reduction protein-NADP+ reductase, the geranylgeranyl pyrophosphate reductase catalyzes the reduction of delta-tocotrienol to generate delta-tocopherol. The geranylgeranyl pyrophosphate reductase has the function of reducing the unsaturated isoprene side chain of tocotrienol, can catalyze the reduction of tocotrienol to generate tocopherol, does not need to depend on the geranyl pyrophosphate precursor in the existing tocopherol biosynthesis pathway, significantly improves the tocopherol synthesis efficiency, and provides a new strategy for the biosynthesis of tocopherol and other tocopherols.

The present invention relates to a process for obtaining minor components from vegetable oils, and wherein the vegetable oil includes palm oil, palm olein, palm mid-fraction or mixtures thereof. The minor components of interest are squalene, tocopherols, and optionally tocotrienols. The process is comprising, a fractionation in a plate short path evaporator. The fractionation is conducted in a plate short path evaporator with at least one evaporation section at a temperature of 140°C to 180°C, followed by at least one evaporation section at temperature of above 180°C to 240°C. The feed stream may be a condensate stream from a deodorization step.

The present invention relates to a process for the preparation of a Vitamin E derivative, in particular to a process for the synthesis of δ-tocotrienol of formula (I).

The invention belongs to the field of light industry grease, and particularly relates to a preparation method and application of base oil with a transdermal absorption characteristic. The method comprises the following steps: taking diglyceride as skin care product emulsion base oil for the first time, taking oleic acid, capric acid and glycerol as raw materials, carrying out catalytic esterification through a specific enzyme method to obtain diglyceride, carrying out molecular distillation purification, and further separating and purifying through a solvent method to control the proportion of 1-oleic acid-3-capric acid diglyceride in the diglyceride, so as to obtain the skin care product emulsion. The base oil which has improved transdermal absorption performance and can be applied to skin care product emulsion is prepared. The composition of diglyceride acyl and the content of isomers (especially 1-oleic acid-3-decanoic acid diglyceride in diglyceride) are controlled, compared with traditional grease, when tocotrienol is delivered, the permeability and the permeation amount per unit area in 24 hours are remarkably improved, and the retention amount of tocotrienol delivered to a corium layer is remarkably increased.

This present disclosure provides various diamine centered poly(amino acid)-saccharide-lipid conjugates. In various embodiments, the conjugates can safely be used as water solubility or bioavailability enhancers. In one aspect, the present disclosure provides a conjugate having the structural formula wherein B is a residue of a compound having three or four available binding positions, e.g., an alkylene diamine; S is a saccharide, for example, a residue of a mono-, di- or trisaccharide group, in which each saccharide unit is a sugar, a sugar alcohol, an amino sugar or a sugar acid; L is a lipophilic carrier residue selected from fatty acid residues (for example, residues of lauric acid, myristic acid, linoleic acid, palmitic acid, oleic acid and elaidic acid), steroid acid and sterol residues, and residues of retinoids carotenoids, tocopherols, and tocotrienols; Q is a residue of ethylene glycol, diethylene glycol, triethylene glycol, tetraethylene glycol, pentaethylene glycol or hexaethylene glycol; P is a residue of a polyaminoacid homopolymer; R2 is a terminal group selected from H, methyl, ethyl and maleimide; D is a secondary group that is as defined above for L or is a methyl-capped poly(ethylene glycol) residue; and d is 0, or d is 1.

This invention discloses a Zmhppd1 gene for detecting gamma-tocotrienol content in sweet corn kernels and its application. The locus is the InDel site at position 86086906 on chromosome 5 of the sweet corn genome, with a polymorphism of - / TAGAACAAGG. This locus is positively correlated with the expression of the 4-hydroxyphenylpyruvate dioxygenase gene, thus affecting gamma-tocotrienol content. This invention utilizes a molecular marker developed based on the 4-hydroxyphenylpyruvate dioxygenase gene (Zmhppd1) locus, employing agarose gel electrophoresis technology. Genotyping can be rapidly performed, offering advantages such as low cost, ease of operation, and suitability for high-throughput detection. This locus will greatly promote biofortification breeding of sweet corn with high gamma-tocotrienol content. This invention, based on the 4-hydroxyphenylpyruvate dioxygenase gene locus, allows for rapid genotyping, offering advantages such as low cost, ease of operation, suitability for high-throughput detection, and promotion of biofortification breeding of sweet corn with high gamma-tocotrienol content.

The application discloses a kind of lipid molecules for nucleic acid delivery and liver microenvironment repair and application, belong to medical biotechnology field, and the lipid molecule is the compound shown in formula (1) or its pharmaceutically acceptable salt, it contains tocopherol or tocol trienol fragment and zinc ion coordination group in its structure, with the chemical and biological function of ionizable lipid and the antioxidant, anti-inflammatory activity of vitamin E and zinc.The lipid nanoparticle comprising the compound can efficiently deliver various nucleic acids, and while releasing in liver target, by eliminating active oxygen, inhibiting inflammatory pathways, actively improving liver microenvironment, reducing oxidative stress and fibrosis damage.The delivery system realizes the synergistic treatment concept of "carrier is medicine", and has wide application prospect in nucleic acid drug treatment and gene vaccine development in chronic liver disease, liver fibrosis, liver cancer and other diseases.

The present invention relates to analogues of non-acidic, fatty, semi-hard fresh cheese and analogues of acidic, fatty, semi-hard fresh cheese, and the production thereof, containing HPO with low saturated fat and sodium content, which confers nutritional and functional characteristics. They are a source of vitamin E in the form of tocotrienol and omega-9 fatty acids.

The application discloses a kind of compound natural antioxidant, compound grease, antioxidant preparation and application thereof.The compound natural antioxidant comprises the following components: oryzanol, vitamin E and phytosterol;Wherein, the mass ratio of oryzanol, vitamin E and phytosterol is (12.5-20):1:(10-25);Vitamin E includes tocotrienol;The mass percentage content of tocotrienol in vitamin E is not less than 30%;Phytosterol includes sitosterol;The mass percentage content of sitosterol in phytosterol is not less than 10%.The compound natural antioxidant of the application has excellent in vitro antioxidant performance, and can also have excellent in vivo antioxidant, anti-aging performance.

Disclosed are compositions comprising delta-tocotrienol and methods for using the same in the prevention of cancer progression. The methods comprise of reducing, inhibiting, decreasing, and / or preventing the progression of a neoplasm to a cancer (including, but not limited to lung cancer, ovarian cancer, breast cancer, rectal cancer, pancreatic, colon cancer, or intraductal papillary mucinous neoplasm (IPMN) to pancreatic ductal adenocarcinoma) in a subject comprising administering to a subject a therapeutically effective amount of a composition comprising delta-tocotrienol (d-T3).

The invention relates to application of gamma-tocotrienol in treatment of non-alcoholic fatty liver disease and / or hepatic fibrosis, in particular to the application of the gamma-tocotrienol in the treatment of the non-alcoholic fatty liver disease and / or hepatic fibrosis, specifically, the gamma-tocotrienol can remarkably relieve hepatic lipid accumulation and inflammation of non-alcoholic steatohepatitis (NASH) caused by high fat diet and can effectively inhibit carbon tetrachloride induced hepatic fibrosis.